UroGen Pharma Ltd.'s SEC filings document operating results, product revenue disclosures, financing agreements and governance matters for a biotechnology company focused on urothelial and specialty cancers. Recent 8-K reports furnish quarterly and annual financial results tied to JELMYTO and ZUSDURI, commercial launch updates, research and development expenses, reimbursement matters and pipeline disclosures involving UGN-103 and UGN-501.
Other filings describe material definitive agreements, including term-loan refinancing and credit arrangements with BioPharma Credit entities, as well as capital-structure information for ordinary shares listed on Nasdaq. Definitive proxy statements cover board matters, executive compensation, equity awards, pay-versus-performance tables and shareholder voting matters.
UroGen Pharma Ltd. filed a Form S-8 to register additional ordinary shares for issuance under its 2017 Equity Incentive Plan. The filing uses General Instruction E to incorporate by reference prior effective S-8 registrations for the same plan. Exhibits include the Israeli legal opinion on share validity, auditor consent, plan documents, and the filing fee table.
UroGen Pharma (URGN) reported Q3 2025 results with revenue of $27,482 thousand, up from $25,204 thousand a year ago, as Jelmyto sales remained the primary driver and newly approved Zusduri contributed initial sales. Gross profit was $24,204 thousand. Operating expenses rose, led by selling, general and administrative costs of $37,582 thousand and research and development of $14,008 thousand, resulting in an operating loss of $27,386 thousand.
Net loss was $33,347 thousand (basic and diluted loss per share of $0.69). For the nine months, revenue reached $71,951 thousand with a net loss of $127,130 thousand. Cash, cash equivalents and marketable securities totaled $127.4 million as of September 30, 2025. The balance sheet reflected a prepaid forward obligation of $126,067 thousand and long‑term debt of $122,111 thousand. Shareholders’ deficit was $115,408 thousand.
Zusduri received FDA approval on June 12, 2025 and generated $1,779 thousand in Q3 sales, while Jelmyto delivered $25,703 thousand. Management stated that available cash and securities are expected to fund operations beyond one year from issuance. The company revised Q3 2024 loss per share to include 3,679,400 pre‑funded warrants in the weighted average shares outstanding.
UroGen Pharma (URGN) reported that it announced financial results for the quarter ended September 30, 2025. The details are provided in a press release furnished as Exhibit 99.1.
The information was furnished under Item 2.02 and is not deemed “filed” under Section 18 of the Exchange Act or incorporated by reference unless specifically stated. UroGen’s ordinary shares trade on Nasdaq under the symbol URGN.
Chris Degnan, Chief Financial Officer of UroGen Pharma Ltd. (URGN), reported equity changes related to restricted stock units. The reporting notes a grant of 13,450 RSUs on 10/08/2024 that vest in three equal annual installments beginning 10/08/2025. On 10/08/2025 the reporting person had 4,483 RSUs treated as acquired upon vesting and sold 2,203 shares to satisfy tax withholding at a price of $16.85 per share. After these transactions the beneficial ownership reported is 8,967 ordinary shares. The Form 4 was signed by an attorney-in-fact on 10/09/2025.
Mark Schoenberg, Chief Medical Officer of UroGen Pharma Ltd. (URGN), received and settled restricted stock units in September 2025. On 09/07/2025 1,667 RSUs vested, each representing one ordinary share, increasing his beneficial ownership to 149,896 shares. On 09/08/2025 he sold 871 shares at $19.11 to satisfy withholding tax obligations, leaving him with 149,025 shares beneficially owned. The RSUs granted on 09/07/2023 totalled 5,000 and vest in three equal annual installments beginning 09/07/2024. The Form 4 was signed by an attorney-in-fact on 09/09/2025.
Insider transactions at UroGen Pharma Ltd. (URGN): Jason D. Smith, General Counsel, had 3,333 restricted stock units (RSUs) vest on 09/07/2025, which converted into 3,333 ordinary shares. On 09/08/2025 he sold 1,520 shares at $19.11 each to satisfy withholding tax obligations following the RSU settlement. After these transactions the reporting person beneficially owned 43,305 ordinary shares. The RSU grant referenced was originally for 10,000 shares, granted 09/07/2023 and vesting in three equal annual installments beginning 09/07/2024.
Form 144 notice for UroGen Pharma Ltd. (URGN) reports a proposed sale of 871 ordinary shares through Oppenheimer & Co. on 09/08/2025 with an aggregate market value of $16,444.48. The shares were acquired as RSUs on 09/07/2023 totaling 3,333 units for this grant, with payment recorded on the acquisition date. The filing also discloses two prior ordinary-share sales by the same seller in the past three months: 5,149 shares on 07/28/2025 for $98,551.86 and 5,162 shares on 06/09/2025 for $38,043.94. The filer affirms no undisclosed material adverse information about the issuer.
UroGen Pharma Ltd. (URGN) filing a Form 144 notifies a proposed sale of 1,520 ordinary shares through Oppenheimer with an aggregate market value of $28,697.60, scheduled approximately for 09/08/2025. The shares were acquired as RSUs on 09/07/2023 (6,666 units reported acquired at that time). The filer also reported a prior sale on 07/28/2025 of 7,522 ordinary shares generating $143,971.08 in gross proceeds. The notice includes the standard representation that the seller is not aware of any undisclosed material adverse information about the issuer. The form identifies the broker as Oppenheimer and shows ~46.26 million shares outstanding for the issuer.
UroGen Pharma insider grant: Director Daniel George was granted equity awards on 08/26/2025 consisting of a stock option to buy 10,000 ordinary shares at an exercise price of $19.50 and 8,000 restricted stock units (RSUs) each representing one ordinary share. The option and RSUs were reported as acquisitions and are held directly. The option and RSU awards vest in equal quarterly installments over one year, subject to the directors continuous service under the 2017 Equity Incentive Plan. The reporting was filed by an attorney-in-fact on 08/27/2025.
UroGen Pharma Ltd. (URGN) director James A. Robinson Jr. reported grants on 08/26/2025 consisting of a stock option and restricted stock units. The stock option is a right to buy 10,000 ordinary shares at an exercise price of $19.50 per share, exercisable through 08/26/2035. The RSUs represent a contingent right to 8,000 ordinary shares. Both the option shares and RSU shares vest in equal quarterly installments over one year, subject to the director's continuous service under the 2017 Equity Incentive Plan. The Form 4 was signed by an attorney-in-fact on 08/27/2025.